Neurocrine Biosciences, Inc.

Informe acción NasdaqGS:NBIX

Capitalización de mercado: US$12.7b

Salud financiera de hoja de balance de Neurocrine Biosciences

Salud financiera controles de criterios 6/6

Neurocrine Biosciences tiene un patrimonio de accionistas total de $2.7B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $3.5B y $816.1M respectivamente. El BAIT de Neurocrine Biosciences es de $602.3M, por lo que su ratio de cobertura de intereses es de -6.9. Tiene efectivo e inversiones a corto plazo que ascienden a $1.2B.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses-6.9x
EfectivoUS$1.23b
PatrimonioUS$2.72b
Total pasivoUS$816.10m
Activos totalesUS$3.54b

Actualizaciones recientes sobre salud financiera

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

The Play On Neurocrine Biosciences

Oct 02

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($1.9B) de NBIX superan a sus pasivos a corto plazo ($429.7M).

Pasivo a largo plazo: Los activos a corto plazo de NBIX ($1.9B) superan a sus pasivos a largo plazo ($386.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: NBIX está libre de deudas.

Reducción de la deuda: NBIX no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 70.2%.

Cobertura de la deuda: NBIX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: NBIX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera